DaVita misses Q3 earnings estimates, maintains full-year outlook By Investing.com
Update: 2025-10-30
Description
DaVita, a leading kidney care provider, reported Q3 earnings that fell short of analysts' expectations, with adjusted earnings of $2.51 per share and revenue of $3.42 billion. Despite this, the company remains confident in its full-year guidance of $10.35 to $11.15 per share. The quarter saw strong performance in patient care and staff investment, with 7.24 million treatments in the U.S. and robust operating and free cash flows. However, a cybersecurity incident and share buybacks impacted the bottom line. DaVita continues to focus on long-term stability and growth, serving nearly 293,000 patients across 3,200 centers in the U.S. and 14 other countries.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
